Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 43,848 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 43,848 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $12.24 per share, with a total value of $536,699.52. Following the completion of the acquisition, the director now owns 17,255,151 shares in the company, valued at $211,203,048.24. This trade represents a 0.25 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, March 24th, Ecor1 Capital, Llc acquired 22,689 shares of Zymeworks stock. The shares were bought at an average price of $13.08 per share, for a total transaction of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The stock was bought at an average price of $12.78 per share, with a total value of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The shares were bought at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The stock was purchased at an average price of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The stock was purchased at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The shares were purchased at an average price of $11.49 per share, with a total value of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The shares were acquired at an average cost of $13.87 per share, with a total value of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was acquired at an average price of $14.01 per share, for a total transaction of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The stock was acquired at an average cost of $13.39 per share, for a total transaction of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were acquired at an average cost of $13.13 per share, with a total value of $2,679,806.74.

Zymeworks Price Performance

Zymeworks stock traded down $0.46 during trading hours on Monday, reaching $11.91. The company had a trading volume of 577,415 shares, compared to its average volume of 598,050. Zymeworks Inc. has a 12-month low of $7.97 and a 12-month high of $17.70. The company has a 50-day moving average price of $13.56 and a 200 day moving average price of $13.74. The firm has a market cap of $828.66 million, a price-to-earnings ratio of -7.94 and a beta of 1.13.

Remove Ads

Analyst Ratings Changes

A number of analysts have recently issued reports on ZYME shares. JPMorgan Chase & Co. raised shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Lifesci Capital started coverage on Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective for the company. Wells Fargo & Company raised their price objective on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. HC Wainwright upped their target price on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday, March 10th. Finally, Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zymeworks has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ZYME. Barclays PLC grew its holdings in Zymeworks by 476.3% in the 3rd quarter. Barclays PLC now owns 154,384 shares of the company's stock worth $1,937,000 after acquiring an additional 127,595 shares during the last quarter. State Street Corp grew its stake in shares of Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares during the last quarter. Vestal Point Capital LP increased its holdings in Zymeworks by 39.8% during the 3rd quarter. Vestal Point Capital LP now owns 615,000 shares of the company's stock valued at $7,718,000 after purchasing an additional 175,000 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Zymeworks by 93.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after buying an additional 311,107 shares during the period. Finally, FMR LLC grew its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after buying an additional 1,525 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.